Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254098 | INTERLEUKIN-2 VARIANTS AND METHODS OF USES THEREOF | December 2020 | April 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17123349 | PHARMACEUTICAL USE OF ACTININ-4 INVOLVED IN INDUCTION OF CERVICAL CANCER | December 2020 | February 2024 | Abandon | 38 | 2 | 0 | No | No |
| 17107554 | Combination Therapies and Uses for Treatment of Demyelinating Disorders | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 16950418 | ANTI-KLK5 ANTIBODIES AND METHODS OF USE | November 2020 | November 2023 | Allow | 36 | 1 | 1 | No | No |
| 17095882 | USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | November 2020 | September 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17077049 | METHODS OF PROGNOSIS AND TREATMENT | October 2020 | November 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 17073498 | FGFR1 AGONISTS AND METHODS OF USE | October 2020 | June 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17068628 | IL-15 AND IL-15R\ALPHA SUSHI DOMAIN BASED IMMUNOCYTOKINES | October 2020 | April 2023 | Allow | 30 | 1 | 0 | No | No |
| 17066410 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | October 2020 | December 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 17045148 | STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | October 2020 | August 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 17024476 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF BIOLOGICAL PREPARATION ON RHEUMATOID ARTHRITIS | September 2020 | May 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17024206 | USE OF PERIPHERAL BLOOD PRO- AND ANTI-INFLAMMATORY CYTOKINE RATIOS AS MARKERS OF IMPLANTATION PRECEDING PREGNANCY | September 2020 | July 2023 | Abandon | 34 | 2 | 1 | No | No |
| 17018915 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS | September 2020 | February 2023 | Allow | 29 | 3 | 0 | No | No |
| 17003847 | CONJUGATES OF AN IL-2 MOIETY AND A POLYMER | August 2020 | November 2023 | Abandon | 38 | 1 | 1 | No | No |
| 17002072 | MULTIPLE-VARIABLE IL-2 DOSE REGIMEN FOR TREATING IMMUNE DISORDERS | August 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16999088 | METHOD AND PLATFORM FOR DETECTING IMMUNOGENICITY OF TUMOR NEOANTIGEN | August 2020 | October 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16997326 | METHOD FOR MONITORING DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM | August 2020 | May 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16986473 | METHODS OF IDENTIFYING AND USING AGENTS FOR TREATING DISEASES ASSOCIATED WITH INTESTINAL BARRIER DYSFUNCTION | August 2020 | April 2023 | Abandon | 32 | 2 | 1 | No | No |
| 16984215 | Inhibitors Of Lactate Transporters For Use In The Treatment Of Inflammatory Diseases | August 2020 | January 2023 | Abandon | 29 | 1 | 0 | No | No |
| 16931788 | ANTIBODY AGAINST HUMAN TGF-B LAP DEGRADATE, AND USE THEREOF | July 2020 | October 2021 | Allow | 15 | 1 | 1 | Yes | No |
| 16962566 | METHOD FOR QUANTITATIVELY DETERMINING A THERAPEUTIC TNF-ALPHA INHIBITOR | July 2020 | October 2023 | Allow | 39 | 2 | 1 | No | No |
| 16926481 | ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF | July 2020 | March 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16916822 | ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF | June 2020 | August 2023 | Allow | 37 | 2 | 0 | Yes | No |
| 16913840 | METHODS OF TREATING OR PREVENTING SERIOUS SYMPTOMS FROM COVID-19 INFECTION | June 2020 | July 2023 | Allow | 37 | 4 | 1 | Yes | No |
| 16913067 | TGF-BETA 3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF | June 2020 | June 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 16908271 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | June 2020 | February 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16889066 | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE | June 2020 | January 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 15931213 | KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS | May 2020 | October 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16868293 | Immune Gene Signatures in Cancer | May 2020 | August 2021 | Abandon | 15 | 1 | 0 | No | No |
| 16755002 | ANTI-IL-33 THERAPY FOR ATOPIC DERMATITIS | April 2020 | May 2021 | Abandon | 13 | 0 | 1 | No | No |
| 16821593 | METHODS FOR DOSING AN ACTIVIN-ACTRIIA ANTAGONIST AND MONITORING OF TREATED PATIENTS | March 2020 | February 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16819629 | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody | March 2020 | March 2023 | Abandon | 36 | 2 | 0 | No | Yes |
| 16819891 | MUTANT NGAL PROTEINS AND USES THEREOF | March 2020 | March 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16813780 | Humanized anti-CCR7 receptor antibodies | March 2020 | October 2021 | Allow | 19 | 1 | 1 | No | No |
| 16645191 | METHODS AND KITS FOR DIAGNOSIS OF FAMILIAL MEDITERRANEAN FEVER | March 2020 | April 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16809606 | ANTI-IL-36R ANTIBODY FORMULATIONS | March 2020 | December 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16807129 | COMBINATION IL-2 IMMUNOCONJUGATE THERAPY | March 2020 | September 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16798247 | UNTARGETED AND TARGETED IL-10 FC-FUSION PROTEINS | February 2020 | February 2024 | Allow | 47 | 4 | 1 | No | No |
| 16798088 | METHOD OF PREDICTING AND DETERMINING THERAPEUTIC EFFECT ON RHEUMATOID ARTHRITIS DUE TO BIOLOGICAL FORMULATION | February 2020 | October 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16640378 | DETECTION OF INSULIN IN SALIVA AND METHODS OF USE THEREOF | February 2020 | March 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16796608 | METHODS FOR TREATING HAIR LOSS DISORDERS | February 2020 | October 2020 | Allow | 8 | 1 | 0 | Yes | No |
| 16782486 | Novel Treatment Method for Cockayne Syndrome | February 2020 | August 2021 | Allow | 18 | 1 | 1 | Yes | No |
| 16633728 | TUMOR VACCINE | January 2020 | November 2022 | Abandon | 34 | 1 | 0 | No | No |
| 16735833 | METHODS FOR DOSING AN ACTRIIB ANTAGONIST AND MONITORING OF TREATED PATIENTS | January 2020 | July 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16626844 | METHODS OF DELAYING AND PREVENTING ACUTE MYELOID LEUKEMIA RELAPSE | December 2019 | May 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16722133 | ANTI-IL-36R ANTIBODIES FOR TREATMENT OF PALMOPLANTAR PUSTULOSIS | December 2019 | November 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16712800 | Method of Treating Cancer with a Cancer Therapy in Combination with Another Therapeutic Agent | December 2019 | April 2024 | Allow | 52 | 3 | 1 | No | No |
| 16712167 | TELOMERASE POLYPEPTIDE VACCINE FOR TREATING CANCER | December 2019 | January 2024 | Allow | 50 | 5 | 1 | No | No |
| 16709810 | PHARMACEUTICAL PREPARATION COMPRISING RECOMBINANT HCG | December 2019 | November 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16704830 | Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin | December 2019 | November 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16619140 | Immunoassay for Human Erythroferrone | December 2019 | October 2021 | Allow | 23 | 1 | 1 | Yes | No |
| 16692574 | COMPOSITION AND METHODS FOR DETECTING CANCER | November 2019 | September 2023 | Allow | 45 | 2 | 1 | No | No |
| 16614570 | DIAGNOSTICS OF GINGIVITIS BASED ON SALIVARY IL-1BETA AND HGF | November 2019 | January 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16614454 | MIC-1 COMPOUNDS AND USES THEREOF | November 2019 | March 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16686373 | METHOD OF TREATING PUSTULAR PSORIASIS WITH ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R) | November 2019 | May 2021 | Allow | 18 | 1 | 1 | No | No |
| 16613968 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | November 2019 | September 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16683124 | METHODS FOR USE OF PROINSULIN TRANSFERRIN FUSION PROTEINS AS PRODRUGS | November 2019 | December 2022 | Abandon | 37 | 2 | 0 | No | No |
| 16660038 | METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMEN | October 2019 | March 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16605356 | IL4/IL13 Receptor Molecule for Veterinary Use | October 2019 | December 2023 | Allow | 50 | 4 | 1 | No | No |
| 16500429 | Cytokine Combination | October 2019 | August 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16500194 | BIOLOGIC FOR THE TREATMENT OF CANCER | October 2019 | February 2024 | Allow | 52 | 3 | 1 | Yes | No |
| 16499780 | SYSTEMS AND METHODS FOR MANUFACTURING BIOLOGICALLY-PRODUCED PRODUCTS | September 2019 | April 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16586698 | COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS | September 2019 | March 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16496397 | FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PREPARING OPHTHALMIC DISEASE TREATMENT,ANTI-INFLAMMATION AND ANTI-TUMOR MEDICAMENT | September 2019 | October 2022 | Allow | 37 | 2 | 1 | Yes | No |
| 16492666 | IL-37 FUSION PROTEIN AND METHODS OF MAKING AND USING SAME | September 2019 | July 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16492555 | SYNTHEKINE COMPOSITIONS AND METHODS OF USE | September 2019 | February 2024 | Abandon | 53 | 2 | 1 | No | No |
| 16544421 | ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF | August 2019 | April 2020 | Allow | 8 | 1 | 0 | No | No |
| 16544648 | ANTI-ANGIOGENESIS FUSION PROTEIN AND USES THEREOF | August 2019 | August 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16482778 | Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure | August 2019 | March 2024 | Abandon | 55 | 2 | 1 | No | No |
| 16482869 | TGFBETA AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY | August 2019 | February 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16512886 | ANTI-IL36R ANTIBODIES | July 2019 | October 2021 | Allow | 27 | 1 | 1 | Yes | No |
| 16478108 | SYSTEMS AND METHODS FOR PRODUCTION OF RECOMBINANT IL-11 IN YEAST | July 2019 | January 2023 | Allow | 42 | 2 | 0 | Yes | No |
| 16512271 | Biomarkers for Systemic Lupus Erythematosus Disease Activity, and Intensity and Flare | July 2019 | September 2022 | Allow | 38 | 2 | 1 | Yes | No |
| 16509161 | PREVENTIVE OR THERAPEUTIC AGENT FOR KIDNEY DISEASE | July 2019 | November 2021 | Allow | 29 | 3 | 1 | No | No |
| 16476380 | PREFERRED PAIRING OF ANTIBODY DOMAINS | July 2019 | May 2024 | Abandon | 58 | 4 | 1 | Yes | No |
| 16473245 | ANTI-PCSK9 ANTIBODY AND USE THEREOF | June 2019 | June 2022 | Allow | 36 | 1 | 1 | Yes | No |
| 16471756 | MYOSTATIN, ACTIVIN OR ACTIVIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OBESITY AND RELATED CONDITIONS | June 2019 | May 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16471509 | IMMUNOCYTOKINES WITH PROGRESSIVE ACTIVATION MECHANISM | June 2019 | March 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16471431 | ANTIBODIES TO IL-37 | June 2019 | September 2021 | Abandon | 27 | 0 | 1 | No | No |
| 16469173 | COMBINATION OF ANT-CD303 AND ANTI-AMHRII ANTIBODIES | June 2019 | January 2022 | Abandon | 31 | 1 | 1 | No | No |
| 16466566 | POLYMERIC NANOPARTICLES PROVIDING NUCLEIC ACIDS ENCODING TNF-a | June 2019 | October 2021 | Allow | 28 | 2 | 1 | Yes | No |
| 16466110 | TREATMENT OF OBESITY AND EATING DISORDERS | June 2019 | August 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16501750 | Lateral flow immunoassay (LFIA) system for measuring reombinant bovine somatotrophin (rBST) in whole milk and other dairy products | June 2019 | October 2023 | Abandon | 52 | 2 | 0 | Yes | No |
| 16424693 | RECOMBINANT CHICKEN INTERLEUKIN-1 BETA PROTEIN FOR PRODUCING ANTIBODY EARLY AND RETAINING FOR A LONGER PERIOD OF TIME AND APPLICATION THEREOF | May 2019 | February 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16422256 | TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF | May 2019 | April 2022 | Allow | 35 | 1 | 1 | Yes | No |
| 16422212 | Methods For Treating Chronic Obstructive Pulmonary Disease Using Benralizumab | May 2019 | September 2022 | Abandon | 40 | 3 | 0 | No | No |
| 16415231 | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody | May 2019 | September 2021 | Allow | 28 | 1 | 1 | Yes | No |
| 16461747 | ENGINEERED TGF-BETA MONOMERS AND THEIR USE FOR INHIBITING TGF-BETA SIGNALING | May 2019 | April 2021 | Allow | 23 | 1 | 0 | Yes | No |
| 16414601 | FGFR1 AGONISTS AND METHODS OF USE | May 2019 | February 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16412543 | IL-17 ANTAGONISTIC ANTIBODIES | May 2019 | August 2022 | Abandon | 39 | 2 | 1 | No | Yes |
| 16393615 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | April 2019 | February 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16393619 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | April 2019 | February 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16342176 | ANTI-IL1-RAP ANTIBODIES | April 2019 | February 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16342275 | ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | April 2019 | October 2023 | Abandon | 54 | 3 | 1 | No | No |
| 16342462 | ASSAY FOR C5B-9 DEPOSITION IN COMPLEMENT-ASSOCIATED DISORDERS | April 2019 | August 2023 | Abandon | 52 | 3 | 0 | Yes | No |
| 16341034 | SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST CTLA-4 | April 2019 | July 2022 | Allow | 39 | 2 | 1 | Yes | No |
| 16334767 | Novel Anti-PCSK9 Antibodies | March 2019 | April 2021 | Allow | 25 | 1 | 1 | Yes | No |
| 16352619 | ANTI-KLK5 ANTIBODIES AND METHODS OF USE | March 2019 | January 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16299382 | METHODS FOR TREATING HAIR LOSS DISORDERS | March 2019 | November 2021 | Allow | 33 | 2 | 1 | No | No |
| 16296582 | USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | March 2019 | December 2020 | Abandon | 21 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCCOLLUM, ANDREA K.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCCOLLUM, ANDREA K works in Art Unit 1646 and has examined 524 patent applications in our dataset. With an allowance rate of 50.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner MCCOLLUM, ANDREA K's allowance rate of 50.6% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCCOLLUM, ANDREA K receive 1.83 office actions before reaching final disposition. This places the examiner in the 39% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MCCOLLUM, ANDREA K is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +47.4% benefit to allowance rate for applications examined by MCCOLLUM, ANDREA K. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.2% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.8% of cases where such amendments are filed. This entry rate is in the 73% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 71.1% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.